Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $22.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $22.00.

A number of equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $19.00 target price on shares of Aura Biosciences in a research report on Friday, May 23rd.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in shares of Aura Biosciences in the fourth quarter worth about $50,000. Tower Research Capital LLC TRC grew its holdings in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after purchasing an additional 2,104 shares during the last quarter. GAMMA Investing LLC increased its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock worth $57,000 after purchasing an additional 9,573 shares in the last quarter. Invesco Ltd. acquired a new position in Aura Biosciences during the 2nd quarter worth approximately $76,000. Finally, ProShare Advisors LLC bought a new position in Aura Biosciences in the 4th quarter valued at approximately $127,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $6.72 on Thursday. Aura Biosciences has a 52 week low of $4.34 and a 52 week high of $12.38. The firm’s 50-day simple moving average is $6.62 and its 200 day simple moving average is $6.52. The firm has a market cap of $417.45 million, a price-to-earnings ratio of -3.43 and a beta of 0.46.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Sell-side analysts anticipate that Aura Biosciences will post -1.66 EPS for the current year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.